NCT00336063 - Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2006

Primary Completion Date

April 19, 2013

Study Completion Date

March 19, 2026

Conditions

Adult Nasal Type Extranodal NK/T-Cell LymphomaRecurrent Nasopharyngeal Keratinizing Squamous Cell CarcinomaRecurrent Nasopharyngeal Undifferentiated CarcinomaStage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7

Interventions

DRUG

Azacitidine

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Vorinostat

Given PO

Trial Locations (5)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

119074

National University Hospital Singapore, Singapore

168583

National Cancer Centre Singapore, Singapore

Unknown

Chinese University of Hong Kong-Prince of Wales Hospital, Shatin

104 0045

National Cancer Center Hospital, Tokyo

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH